Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus MIRADON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COUMADIN versus MIRADON.
COUMADIN vs MIRADON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
MIRADON (anagrelide) inhibits cyclic nucleotide phosphodiesterase and the release of arachidonic acid from phospholipids, possibly by inhibiting phospholipase A2. It also suppresses megakaryocyte maturation and platelet production.
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
2.5 mg orally twice daily (total daily dose 5 mg)
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
Terminal elimination half-life is 8-12 hours in adults with normal renal function. In patients with creatinine clearance <30 mL/min, half-life may extend to 20-30 hours. The half-life supports twice-daily dosing in most patients.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Renal excretion of unchanged drug accounts for 60-70% of the administered dose. Fecal/biliary excretion accounts for 20-25%, with the remainder as oxidative metabolites. Up to 10% is eliminated as glucuronide conjugates.
Category C
Category C
Anticoagulant
Anticoagulant